271 related articles for article (PubMed ID: 37289729)
1. Computational simulations of tumor growth and treatment response: Benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization.
Nikmaneshi MR; Jain RK; Munn LL
PLoS Comput Biol; 2023 Jun; 19(6):e1011131. PubMed ID: 37289729
[TBL] [Abstract][Full Text] [Related]
2. Investigation of cancer response to chemotherapy: a hybrid multi-scale mathematical and computational model of the tumor microenvironment.
Nikmaneshi MR; Firoozabadi B
Biomech Model Mechanobiol; 2022 Aug; 21(4):1233-1249. PubMed ID: 35614373
[TBL] [Abstract][Full Text] [Related]
3. Chemo-mechanistic multi-scale model of a three-dimensional tumor microenvironment to quantify the chemotherapy response of cancer.
Nikmaneshi MR; Firoozabadi B; Mozafari A
Biotechnol Bioeng; 2021 Oct; 118(10):3871-3887. PubMed ID: 34133020
[TBL] [Abstract][Full Text] [Related]
4. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy.
Li S; Zhang Q; Hong Y
Technol Cancer Res Treat; 2020; 19():1533033820980116. PubMed ID: 33287656
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic nano-delivery system promotes tumor vascular normalizing and micro-environment reprogramming in solid tumor.
Shen R; Peng L; Zhou W; Wang D; Jiang Q; Ji J; Hu F; Yuan H
J Control Release; 2022 Sep; 349():550-564. PubMed ID: 35841997
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J; Mortezaee K
Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
[TBL] [Abstract][Full Text] [Related]
7. Combining microenvironment normalization strategies to improve cancer immunotherapy.
Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
[TBL] [Abstract][Full Text] [Related]
8. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor vascularization: promising strategies for vascular normalization.
Zheng R; Li F; Li F; Gong A
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
[TBL] [Abstract][Full Text] [Related]
10. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.
Lai V; Neshat SY; Rakoski A; Pitingolo J; Doloff JC
Adv Drug Deliv Rev; 2021 Dec; 179():113920. PubMed ID: 34384826
[TBL] [Abstract][Full Text] [Related]
12. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
13. The application and research progress of anti-angiogenesis therapy in tumor immunotherapy.
Tu J; Liang H; Li C; Huang Y; Wang Z; Chen X; Yuan X
Front Immunol; 2023; 14():1198972. PubMed ID: 37334350
[TBL] [Abstract][Full Text] [Related]
14. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
15. Role of vascular normalization in benefit from metronomic chemotherapy.
Mpekris F; Baish JW; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262
[TBL] [Abstract][Full Text] [Related]
16. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
17. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Fukumura D; Jain RK
Microvasc Res; 2007; 74(2-3):72-84. PubMed ID: 17560615
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
Choi SH; Yoo SS; Lee SY; Park JY
Arch Pharm Res; 2022 Apr; 45(4):263-279. PubMed ID: 35449345
[TBL] [Abstract][Full Text] [Related]
19. Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy.
Cai Y; Zhang J; Li Z
Biomed Eng Online; 2016 Dec; 15(Suppl 2):155. PubMed ID: 28155728
[TBL] [Abstract][Full Text] [Related]
20. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
